HTG releases second white paper on its transcriptome-based approach to drug discovery
TUCSON, Ariz., July 06 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life sciences company advancing precision medicine with its innovative transcriptome-scale profiling technology, published a second white paper (the “White Paper”), further establishing the utility of its transcriptome-based approach to drug design and discovery using its proprietary HTG EdgeSeq technology.
“We cannot overemphasize the need to accelerate the drug discovery process by designing and selecting molecules with a better chance of success, with the goal of enabling new treatments to reach patients as quickly and as effectively. as possible,” said Dr. Stephen Barat, Senior Vice President. President of Therapeutics at HTG. “We believe the studies described in the white paper further support the power of our transcriptome-based drug discovery and design platform and the central role it can play in achieving this goal.”
The cornerstone of HTG’s therapeutic activity, the HTG Transcriptome Panel (HTP) was launched with commercial availability in August 2021. The HTP was designed to enable the evaluation of approximately 20,000 mRNA targets at the using HTG’s EdgeSeq technology, a targeted RNA sequencing technology that couples a nuclease protection assay with next-generation sequencing for fast and accurate RNA quantification. The many advantages of HTG EdgeSeq include a 96-well plate format, low sample input requirement, no RNA extraction, and fast test and analysis time. We believe these advantages make it an attractive technology for applying transcriptomic profiling to drug discovery.
The white paper describes the use of the HTG transcriptome-based drug design and discovery platform in the design, screening and early-stage characterization of candidate small molecules for an initial therapeutic target. The results of the studies summarized in the white paper revealed several indication-specific effects as well as potential adverse effects of the initial therapeutic target through analysis of transcriptomic profiles from test systems of human cell lines treated with the compound. The white paper is available here.
HTG intends to use the process described in the white paper to further refine the design of its small molecule chemical libraries. This should enable the selection and characterization of candidate molecules among selected therapeutic targets of interest, potentially leading to commercial development and licensing opportunities in various therapeutic areas. A video providing an overview of HTG’s therapeutic activities is available on the company’s website. website.
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-scale profiling to drive translational research, novel therapies, and clinical diagnostics in a variety of disease areas.
Backed by more than a decade of pioneering innovations and partnerships with leading biopharmaceuticals and leading academic institutes, HTG’s proprietary RNA platform technologies are designed to make tool and diagnostic development more effective and efficient life sciences and to unlock a differentiated and disruptive approach to drug discovery transformation. For more information, visit www.htgmolecular.com.
Statements in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities and benefits of HTP and its potential impact on the drug. discovery process, HTG’s intention to further refine the design of its small molecule chemical libraries, future commercial development and licensing opportunities, and other potential benefits of the RNA platform and technologies from HTG. Words such as “may”, “designed”, “aim”, “intend”, “believe”, “will”, “potential” and similar expressions are intended to identify forward-looking statements, although not all statements necessarily contain these identifying words. These forward-looking statements are based on management’s current expectations, are subject to known and unknown risks and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties, including, without limitation, risks associated with drug discovery and development; the risk that HTP and our RNA platform and medicinal chemistry technologies may not provide the benefits we expect; risks associated with our ability to develop and commercialize our products; the risk that our products and services will not be adopted by biopharmaceutical companies or other customers as expected, or at all; our ability to manufacture our products to meet demand; competition in our industry; additional availability of capital and credit; our ability to attract and retain qualified personnel; risks associated with the impact of the COVID-19 pandemic on us and our customers; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as filed with the SEC on May 12, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update update these statements to reflect events that occur or circumstances that exist after the date on which they were made.
Phone: (617) 430-7577
E-mail: [email protected]